Lantheus (NASDAQ:LNTH) Issues FY 2025 Earnings Guidance

Key Points

• Lantheus provided its FY 2025 earnings guidance with an EPS forecast of 5.500-5.700, which is below the consensus estimate of 6.641.
• The company's revenue guidance is set at $1.5 billion, compared to a consensus expectation of $1.6 billion.
• Lantheus stock traded up $3.10 to reach $54.97, with a substantial trading volume of over 3 million shares compared to its average of about 1 million shares.

Lantheus (NASDAQ:LNTH - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 5.500-5.700 for the period, compared to the consensus EPS estimate of 6.641. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.6 billion.

Lantheus Stock Performance

LNTH stock traded up $3.10 during trading on Thursday, hitting $54.97. The company had a trading volume of 3,131,229 shares, compared to its average volume of 1,114,076. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. The firm has a market cap of $3.80 billion, a PE ratio of 15.62 and a beta of 0.14. Lantheus has a 1-year low of $47.25 and a 1-year high of $118.21. The firm has a 50-day moving average price of $77.09 and a 200-day moving average price of $87.42.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.69 earnings per share. On average, analysts expect that Lantheus will post 6.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of research reports. Truist Financial reduced their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Mizuho cut their price objective on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday. B. Riley decreased their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, JMP Securities reduced their price objective on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $114.50.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.